SCHEMBL1016379

SCHEMBL1016379

CC(=O)c1ccc(N2CC3CC2CN3C(=O)OC(C)(C)C)cc1C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.45
HSD11B1 P28845 1/20 0.44
HDAC1 Q13547 1/20 0.44
PARP1 P09874 1/20 0.43
IDH1 O75874 1/20 0.40
F13A1 P00488 1/20 0.39
TGM2 P21980 1/20 0.39
TGM1 P22735 1/20 0.39
AR P10275 3/20 0.39
NR1H2 P55055 2/20 0.39
NR1H3 Q13133 2/20 0.39
RET P07949 2/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
SPR P35270 1/20 0.38
MAPK8 P45983 1/20 0.37
FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016380 1.00 GPR119 (0.45) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL1016066 0.88 GPR119 (0.44) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL1017779 0.88 GPR119 (0.44) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL1016065 0.88 GPR119 (0.44) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL3498139 0.85 HDAC1 (0.49) GPR119HSD11B1HDAC1PARP1F13A1
SCHEMBL30964844 0.84 GPR119 (0.45) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL1017414 0.84 GPR119 (0.42) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL1017413 0.84 GPR119 (0.42) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL1017415 0.84 GPR119 (0.42) GPR119HSD11B1HDAC1PARP1IDH1
SCHEMBL30964970 0.83 NR1H2 (0.44) GPR119HSD11B1HDAC1PARP1IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271649-A1 BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF Wyeth LLC (US) 2011-01-12 EP disclosed
US-20100029657-A1 Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof WYETH (US) 2010-02-04 US disclosed
WO-2009108838-A1 BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF WYETH (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029657-A1 Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof BRAF, RAF1, ARAF GPR119 2939/4885HSD11B1 2299/4885HDAC1 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.